Day: March 22, 2022

VANCOUVER, Wash., March 22, 2022 (GLOBE NEWSWIRE) — Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today reported financial and operating results for the quarter and full year ended December 31, 2021. “Our progress this quarter capped off a remarkable year for Absci from start to finish,” said Sean McClain, Founder and CEO. “In the last few months alone, we announced collaborations with EQRx and Merck including six drug discovery programs in total. And earlier today we shared data around some of our groundbreaking AI models for therapeutic protein design and optimization. These achievements, enabled by our proprietary assay data and platform, advance the state-of-the-art, and we are collaborating with NVIDIA...

Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., March 22, 2022 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, provides a business update and reports financial results for the three and twelve months ended December 31, 2021. “Caladrius made significant progress in 2021 that we believe has positioned us well to achieve several important milestones in 2022,” stated David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius. “Highlights from 2021 include the initiation of our ongoing Phase 2b FREEDOM Trial of XOWNA® for the treatment of coronary microvascular dysfunction; the appointment of Kristen K. Buck, M.D.,...

Third quarter sales of $452 million, up 10% over the prior year Third quarter GAAP diluted earnings per share from continuing operations of $0.63 compared to $0.87 in Q3 FY2021, which included a favorable impact from CARES Act payroll support Adjusted diluted earnings per share from continuing operations of $0.63, up 70% from $0.37 in Q3 FY2021 Third quarter cash flow from operating activities from continuing operations of $16 millionWOOD DALE, Ill., March 22, 2022 (GLOBE NEWSWIRE) — AAR CORP. (NYSE: AIR) today reported third quarter Fiscal Year 2022 consolidated sales of $452.2 million and income from continuing operations of $22.6 million, or $0.63 per diluted share. For the third quarter of the prior year, the Company reported sales of $410.3 million and income from continuing operations of $31.1 million, or $0.87 per diluted...

MaxCyte Provides Initial 2022 Guidance GAITHERSBURG, Md., March 22, 2022 (GLOBE NEWSWIRE) — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. The Company today announced fourth quarter and full year ended December 31, 2021 financial results and provided initial 2022 revenue guidance. Fourth Quarter and Year HighlightsRecord quarterly revenue of $10.2 million up 19% over Q4 2020 was driven by strength in the core business; with growth in core business revenue from cell therapy customers of 43% and drug discovery customers of 32%. Record full-year total revenue of $33.9 million, up 30% over 2020, which was driven...

SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) — Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided financial guidance for 2022. “Codex DNA’s first year as a publicly traded company was successful and productive, as we achieved significant financial and operational objectives,” said Todd R. Nelson, PhD, CEO of Codex DNA. “We also took a number of critical steps in the fourth quarter to lay the foundation for the next phase of our growth, which included signing a substantial early access collaboration and licensing agreement with Pfizer, closing a highly strategic acquisition of Eton Bioscience and achieving outstanding progress in our innovative enzymatic DNA synthesis program. I am grateful...

EMERYVILLE, Calif., March 22, 2022 (GLOBE NEWSWIRE) — Biotechnology company Zymergen Inc. (“Zymergen” or the “Company”), today reported preliminary financial results for the fourth quarter and full year ended December 31, 2021. “Our strategy is committed to bringing products to market by designing and producing molecules, microbes, and materials for diverse end markets across advanced materials, drug discovery and automation,” said Zymergen’s interim CEO, Jay Flatley. “We have implemented a rigorous product development process which evaluates programs through stringent phase gates that verify aspects of the market, the product, and the team resources to fully develop that product to launch. Ahead of the process, we have a robust research engine to create a pipeline of new opportunities that we believe have high potential. We are...

Company Exceeds $1 Billion in Annual Net Sales and Delivers Record Profitability Strong Market Demand, Combined with Continued Execution Against Global Supply Chain Pressures, Drives Record Operating Results Company Introduces Financial Outlook for Fiscal 2022 CHARLOTTE, N.C., March 22, 2022 (GLOBE NEWSWIRE) — Snap One Holdings Corp. (NASDAQ: SNPO) (“Snap One,” the “Company,” “we” or “our”), a provider of smart living products, services, and software to professional integrators, reported financial results for the fiscal fourth quarter and full year ended December 31, 2021. Fiscal Full Year 2021 and Recent Operational HighlightsAchieved several broader company goals:Completed successful initial public offering Rebranded as Snap One (formerly SnapAV) to reflect the Company’s aspiration to be the one partner that professional...

Six Quarterly Records: AVISE® CTD Volume, Testing Revenue, Testing Gross Margin, Testing Gross Margin Percent, Adopters, and Ordering Healthcare Providers SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year ended December 31, 2021. Recent Highlights:Record total revenue of $48.3 million for the year ended December 31, 2021, and total revenue of $12.7 million for the fourth quarter of 2021. Record AVISE® CTD, including AVISE® Lupus, revenue of $39.2 million for the year ended December 31, 2021, a 34.1% increase over 2020, and revenue of $10.4 million for the fourth quarter of 2021, a 21.2% increase over the fourth quarter of 2020. Record 128,246 flagship AVISE® CTD tests, including AVISE®...